JAZZ - outstanding 2Q earnings contribute to 4.76% rise ahead of FDA panel

JAZZ pharmaceuticals announced better-than-expected earnings report for the second quarter of 2010 after the closing bell today, pushing the share price above the $10 mark briefly before settling at $9.90 during after-hour trading.  The EPS (earnings per share) of $0.28, according to the company's press release, was markedly higher than analysts' estimate of $0.14.  Upward momentum is expected to persist as the biotech company approaches FDA panel discussion (Aug 20) regarding its end-stage product candidate, JZP-6.  Read more about JAZZ and JZP-6.